Immediate Impact
4 from Science/Nature 63 standout
Citing Papers
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
Chimeric antigen receptor T cell therapy for autoimmune disease
2024 Standout
Works of Anna Vanazzi being referenced
Rituximab in Hodgkin lymphoma: Is the target always a hit?
2010
High activity 90Y‐ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B‐cell non‐Hodgkin lymphomas
2007
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Anna Vanazzi | 243 | 157 | 61 | 97 | 41 | 339 | |
| Barbara Jezeršek Novaković | 178 | 160 | 46 | 59 | 41 | 387 | |
| Manuela Arcamone | 277 | 187 | 42 | 47 | 24 | 349 | |
| Linda M. Sanders | 199 | 122 | 58 | 54 | 31 | 365 | |
| Ingrid Vášová | 216 | 177 | 43 | 39 | 39 | 328 | |
| Sabela Bobillo | 253 | 188 | 31 | 31 | 39 | 404 | |
| R Ricco | 107 | 76 | 52 | 33 | 48 | 381 | |
| Stefan V. Dubois | 322 | 151 | 92 | 109 | 24 | 407 | |
| Noraidah Masir | 202 | 158 | 48 | 37 | 47 | 384 | |
| Hanne Kuitunen | 250 | 159 | 39 | 21 | 43 | 352 | |
| Sarah C. Rutherford | 255 | 196 | 36 | 25 | 51 | 395 |
All Works
Login with ORCID to disown or claim papers
Loading papers...